Howard L Kaufman

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi The role of poxviruses in tumor immunotherapy
    Howard L Kaufman
    Department of Surgery and Pathology, College of Physicians and Surgeons, Columbia University, 630 W 168th Street, New York, NY 10032, USA
    Surgery 134:731-7. 2003
  2. doi Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma
    Howard L Kaufman
    Department of Surgery, Medicine and Immunology, Rush University Medical Center, Chicago, IL, USA
    Ann Surg Oncol 17:718-30. 2010
  3. pmc A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer
    R S DiPaola
    The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA
    J Transl Med 4:1. 2006
  4. pmc Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma
    Howard L Kaufman
    Department of Surgery, Columbia University, New York, NY 10032, USA
    J Clin Invest 115:1903-12. 2005
  5. pmc Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
    Howard L Kaufman
    Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    J Transl Med 7:2. 2009
  6. ncbi Clinical protocol. Intra-Lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer
    Howard L Kaufman
    Department of Surgery, Columbia Presbyterian Medical Center, New York, NY 10032, USA
    Hum Gene Ther 14:803-27. 2003
  7. pmc Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer
    Howard L Kaufman
    The Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    J Transl Med 5:60. 2007
  8. ncbi Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors
    Howard L Kaufman
    Tumor Immunology Laboratory, Department of Surgery, Columbia University, New York, NY 10032, USA
    Hum Gene Ther 17:239-44. 2006
  9. doi Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer
    Howard L Kaufman
    Columbia University Medical Center, New York, New York 10032, USA
    Clin Cancer Res 14:4843-9. 2008
  10. ncbi Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group
    Howard L Kaufman
    Columbia University Medical Center, 177 Fort Washington Avenue, New York, NY 10032, USA
    J Clin Oncol 22:2122-32. 2004

Research Grants

Collaborators

Detail Information

Publications58

  1. ncbi The role of poxviruses in tumor immunotherapy
    Howard L Kaufman
    Department of Surgery and Pathology, College of Physicians and Surgeons, Columbia University, 630 W 168th Street, New York, NY 10032, USA
    Surgery 134:731-7. 2003
  2. doi Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma
    Howard L Kaufman
    Department of Surgery, Medicine and Immunology, Rush University Medical Center, Chicago, IL, USA
    Ann Surg Oncol 17:718-30. 2010
    ..The work reported herein was performed to better characterize the effect of vaccination on local and distant antitumor immunity...
  3. pmc A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer
    R S DiPaola
    The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA
    J Transl Med 4:1. 2006
    ....
  4. pmc Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma
    Howard L Kaufman
    Department of Surgery, Columbia University, New York, NY 10032, USA
    J Clin Invest 115:1903-12. 2005
    ..The local delivery of vaccinia virus expressing B7.1 was well tolerated and represents an innovative strategy for altering the local tumor microenvironment in patients with melanoma...
  5. pmc Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
    Howard L Kaufman
    Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    J Transl Med 7:2. 2009
    ..A modified vaccinia virus Ankara (MVA) encoding 5T4 was tested in combination with high-dose IL-2 to determine the safety, objective response rate and effect on humoral and cell-mediated immunity...
  6. ncbi Clinical protocol. Intra-Lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer
    Howard L Kaufman
    Department of Surgery, Columbia Presbyterian Medical Center, New York, NY 10032, USA
    Hum Gene Ther 14:803-27. 2003
  7. pmc Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer
    Howard L Kaufman
    The Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    J Transl Med 5:60. 2007
    ....
  8. ncbi Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors
    Howard L Kaufman
    Tumor Immunology Laboratory, Department of Surgery, Columbia University, New York, NY 10032, USA
    Hum Gene Ther 17:239-44. 2006
    ....
  9. doi Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer
    Howard L Kaufman
    Columbia University Medical Center, New York, New York 10032, USA
    Clin Cancer Res 14:4843-9. 2008
    ..This study was conducted to assess the effects of systemic chemotherapy on ALVAC-CEA/B7.1-induced T-cell immunity in patients with metastatic colorectal cancer...
  10. ncbi Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group
    Howard L Kaufman
    Columbia University Medical Center, 177 Fort Washington Avenue, New York, NY 10032, USA
    J Clin Oncol 22:2122-32. 2004
    ..The induction of PSA-specific immunity was also evaluated...
  11. ncbi Optimizing prostate cancer treatment by combining local radiation therapy with systemic vaccination
    Howard L Kaufman
    Department of Surgery, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Clin Cancer Res 11:6757-62. 2005
  12. ncbi Manipulating the local tumor microenvironment with poxviruses expressing costimulatory molecules
    Howard L Kaufman
    Columbia University Medical Center, 177 Fort Washington Avenue, MHB 7SK, New York, NY 10032, USA
    Ann N Y Acad Sci 1062:41-50. 2005
    ..Herein, we review the general rationale for this approach, discuss the results of ongoing clinical trials, and highlight critical questions that can be addressed in well-designed preclinical and clinical studies...
  13. ncbi Panniculitis after vaccination against CEA and MUC1 in a patient with pancreatic cancer
    Howard L Kaufman
    Department of Surgical Oncology, Columbia University, New York, NY, USA
    Lancet Oncol 6:62-3. 2005
  14. pmc Immune system versus tumor: shifting the balance in favor of DCs and effective immunity
    Howard L Kaufman
    Department of Surgery, Columbia University, New York, New York 10032, USA
    J Clin Invest 113:664-7. 2004
    ....
  15. ncbi Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma
    Giovanni C Cesana
    Tumor Immunology Laboratory, Department of Surgery and Biostatistics, Columbia University Medical Center, New York, NY 10032, USA
    J Clin Oncol 24:1169-77. 2006
    ..To characterize the number and functional status of CD4+CD25+ regulatory T cells (Tregs) in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) treated with high-dose bolus interleukin-2 (IL-2)...
  16. ncbi Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer
    Seunghee Kim-Schulze
    Division of Surgical Oncology, The Tumor Immunology Laboratory, Columbia University, New York, NY 10032, USA
    J Immunol 181:8112-9. 2008
    ..Thus, intrarectal vaccination induces mucosal and systemic antitumor immunity and prevents progression of spontaneous colorectal cancer. These results have implications for the prevention of colorectal cancer in high-risk individuals...
  17. ncbi Gene therapy with poxvirus vectors
    Dorota Moroziewicz
    Columbia University, Department of Surgery, 177 Fort Washington Avenue, MHB 7SK, New York, NY 10032, USA
    Curr Opin Mol Ther 7:317-25. 2005
    ..This review focuses on the current status of recombinant poxviruses as vectors for gene therapy of human disease...
  18. pmc Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment
    Seunghee Kim-Schulze
    The Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, New York, USA
    Mol Ther 17:380-8. 2009
    ..These data suggest that local IL-21 enhances endogenous and adoptively transferred T-cell immunity through increased effector CD8(+) T cells and decreased CD4(+) regulatory T cells in the tumor microenvironment...
  19. ncbi The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells
    Kenneth Flanagan
    Department of Pathology, Columbia University, New York, NY 10032, USA
    Cell Immunol 231:75-84. 2004
    ..The coordinated effects of CCL21 on T cell migration and activation may also represent a more comprehensive paradigm for the activity of other chemokines as well...
  20. ncbi Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response
    Kenneth Flanagan
    Department of Pathology, Columbia University, 177 Fort Washington Avenue, MHB 7 SK, New York, NY 10032, USA
    Vaccine 22:2894-903. 2004
    ....
  21. ncbi Poxviruses as vectors for cancer immunotherapy
    Heesun Kwak
    Columbia University College of Physicians and Surgeons, Departments of Surgery and Pathology, 177 Fort Washington Avenue, MHB 7SK, New York, NY 10032, USA
    Curr Opin Drug Discov Devel 6:161-8. 2003
    ..In this review, we focus on recent advances in the use of poxvirus-based vaccines as cancer therapeutic agents...
  22. ncbi Chemokines in tumor immunotherapy
    Kenneth Flanagan
    Department of Pathology, Columbia University, New York, NY 10032, USA
    Front Biosci 11:1024-30. 2006
    ..This article will briefly review the current understanding of chemokines biology of defined chemokines that are thought to be involved in tumor growth, metastasis, and the host immune response against cancer...
  23. ncbi Immunotherapy for pancreatic cancer: current concepts
    Howard L Kaufman
    Department of Surgery, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Hematol Oncol Clin North Am 16:159-97, viii. 2002
    ..The development of pancreatic cancer vaccines represents a useful paradigm for the translation of basic research into the clinical arena...
  24. doi Imaging the immune response to monitor tumor immunotherapy
    Qin Wang
    Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY, USA
    Expert Rev Vaccines 8:1427-37. 2009
    ..This review will explain some of the more established imaging techniques and discuss their role in monitoring the immune response in patients treated with various tumor immunotherapy approaches...
  25. ncbi Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles
    Michal Bereta
    Department of Surgery and Pathology, Columbia University, New York, New York, USA
    Cancer Gene Ther 11:808-18. 2004
    ..These results highlight the complex immune regulatory effects of rV-CD40L defined by the cumulative effects of CD40L expression, presence of CD40L protein in viral particles, and the replication potential of the virus...
  26. ncbi Immunotherapy for melanoma
    Ian Komenaka
    Section of Surgical Oncology and Department of Pathology, Columbia University College of Physicians and Surgeons, New York, New York, USA
    Clin Dermatol 22:251-65. 2004
    ..The use of immunotherapy in combination with other therapeutic agents and genetic profiling to predict responses suggests that immunotherapy will continue to play a role in the treatment of melanoma...
  27. ncbi Cytokine therapy for cancer
    Seunghee Kim-Schulze
    The Tumor Immunology Laboratory, Division of Surgical Oncology, 622 West 168th Street, Columbia University, New York, NY 10032, USA
    Surg Oncol Clin N Am 16:793-818, viii. 2007
    ..A better understanding of cytokine biology, coupled with new insights into the role of immunoregulation and the microenvironment in patients who have cancer, has provided new therapeutic targets for the treatment of human cancer...
  28. ncbi The tumour microenvironment and implications for cancer immunotherapy
    Christian A Petrulio
    Columbia University, The Tumour Immunology Laboratory, 177 Fort Washington Avenue, MHB 7SK, New York, NY 10032, USA
    Expert Opin Biol Ther 6:671-84. 2006
    ....
  29. ncbi Local delivery of poxvirus vaccines for melanoma
    Heidi Horig
    Department of Surgery, Columbia University Medical Center, 177 Fort Washington Avenue, MHB 7SK, New York, NY 10032, USA
    Semin Cancer Biol 13:417-22. 2003
    ..These studies may have important implications for the design of vaccine strategies for melanoma and other tumors...
  30. doi Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand
    Hong Sung Kim
    Department of Oncological Sciences, Mount Sinai School of Medicine, New York, New York10029, USA
    Cancer Res 69:8516-25. 2009
    ..These data suggest that vaccination with rV-4-1BBL in the setting of host nonmyeloablative lymphodepletion represents a logical strategy for improving oncolytic vaccination in melanoma, and perhaps other cancers as well...
  31. ncbi Prostate-specific antigen vaccines for prostate cancer
    Heidi Horig
    Columbia University, New York, NY, USA
    Expert Opin Biol Ther 2:395-408. 2002
    ....
  32. ncbi Poxvirus vaccines for cancer and HIV therapy
    Shaffiq Essajee
    Department of Surgery and Pathology, Columbia University, New York, NY, USA
    Expert Opin Biol Ther 4:575-88. 2004
    ..In addition, the review aims to identify some of the factors that may shape the development of future therapies based on recombinant poxviruses...
  33. ncbi CEA-based vaccines
    Emina H Huang
    Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Expert Rev Vaccines 1:49-63. 2002
    ....
  34. ncbi Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity
    Howard L Kaufman
    Departments of Microbiology and Immunology and Surgery, Chanin Room 30ZE, Albert Einstein College of Medicine, New York, NY 10461, USA
    Vaccine 20:1862-9. 2002
    ..The use of vaccinia virus for the insertion of other heterologous gene combinations may provide a powerful and less toxic approach for novel vaccination strategies in the treatment and prevention of cancer...
  35. ncbi Herpes simplex virus oncolytic vaccine therapy in melanoma
    Shanthi Sivendran
    The Mount Sinai School of Medicine, The Tisch Cancer Institute, Division of Hematology Oncology, Department of Medicine, New York, NY 10029, USA
    Expert Opin Biol Ther 10:1145-53. 2010
    ..New therapies are clearly needed. JSI/34.5-/47-/GM-CSF is a herpes simplex virus-1 (OncoVEX(GM-CSF)) oncolytic vaccine therapy designed to induce local and systemic anti-tumor immune responses...
  36. ncbi Adjuvant therapy for malignant melanoma
    John P Stoutenburg
    Division of Medical Oncology, Department of Medicine, College of Physicians and Surgeons, Columbia University Medical Center, New York 10032, USA
    Expert Rev Anticancer Ther 4:823-35. 2004
    ..New approaches and novel combinations that appear promising for the adjuvant therapy of malignant melanoma are also outlined...
  37. ncbi TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development
    Dae Won Kim
    Tumor Immunology Laboratory, Department of General Surgery, Rush University Medical Center, Chicago, IL, USA
    Hum Vaccin 6:784-91. 2010
    ..Herein, we review the results of these clinical studies, discuss the lessons learned through these trials and provide some insight into the future development of TroVax as a cancer vaccine...
  38. ncbi Gene therapy for antitumor vaccination
    Seunghee Kim-Schulze
    The Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    Methods Mol Biol 542:515-27. 2009
    ..This chapter reviews the details and major issues related to using live, replicating, recombinant poxviruses for gene delivery and antitumor vaccination within the tumor microenvironment...
  39. ncbi Targeting costimulatory pathways for tumor immunotherapy
    Robert C Ward
    The Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, New York 10032, USA
    Int Rev Immunol 26:161-96. 2007
    ....
  40. ncbi Development of the PANVAC-VF vaccine for pancreatic cancer
    Christian A Petrulio
    The Tumor Immunology Laboratory, Columbia University, New York, NY 10032, USA
    Expert Rev Vaccines 5:9-19. 2006
    ....
  41. ncbi Characteristics of patients diagnosed with both melanoma and renal cell cancer
    Michael R Abern
    Division of Urology, Department of Surgery, Duke Cancer Institute, Duke University Medical Center, 200 Trent Drive, DUMC Box 2804, Durham, NC, 27710, USA
    Cancer Causes Control 24:1925-33. 2013
    ..Patients with renal cell carcinoma (RCC) and malignant melanoma (MM) have an increased risk of additional malignancies. We identified characteristics of MM and RCC associated with a patient developing both cancers...
  42. ncbi Viral vaccines for cancer immunotherapy
    Andrew Eisenberger
    Division of Surgical Oncology and The Tumor Immunology Laboratory, Department of Surgery, Columbia University, New York, NY 10032, USA
    Hematol Oncol Clin North Am 20:661-87. 2006
    ..The biology supporting these viruses as vaccines is reviewed and clinical progress is reported...
  43. ncbi TG-4010 Transgene
    Seth Cohen
    Department of Surgery, Columbia University, 177 Fort Washington Avenue, New York, NY 10032, USA
    Curr Opin Investig Drugs 5:1319-28. 2004
    ..Phase II trials are underway for non-small-cell lung cancer, metastatic renal cancer and prostate cancer...
  44. ncbi Surgical treatment of stage IV melanoma
    Kathryn Spanknebel
    Department of General Surgery, Columbia University College of Physicians and Surgeons, New York, New York, USA
    Clin Dermatol 22:240-50. 2004
    ..Because the majority of post-surgical metastatic patients eventually relapse and succumb to distant disease, adjuvant immunotherapeutic strategies are currently being evaluated...
  45. ncbi Chemokines and cancer
    Kenneth Flanagan
    Department of Pathology, College of Physicians and Surgeons, Columbia University, 622 West 168th Street, New York, NY 10032, USA
    Cancer Invest 20:825-34. 2002
  46. pmc Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies
    Michal Bereta
    Department of Immunology, Jagiellonian University Medical School, Krakow, Poland
    Vaccine 25:4183-92. 2007
    ..The display of antibody fragments on the surface of VNP represents a novel strategy for both targeting CEA-expressing tumors and increasing the immunogenicity of Salmonella-based vaccines for cancer...
  47. ncbi Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide
    Sandeep Soni
    Department of Pediatric Hematology Oncology, Albert Einstein College of Medicine, Ney York 10032, USA
    J Pediatr Hematol Oncol 24:488-91. 2002
    ..Further study of this combination in children with immune-responsive tumors is warranted...
  48. ncbi Pox viral vaccine approaches
    Philip M Arlen
    Laboratory of Tumor Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Semin Oncol 32:549-55. 2005
    ....
  49. pmc 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines
    Chie Kudo-Saito
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 24:4975-86. 2006
    ..1, ICAM-1, and LFA-3)...
  50. ncbi Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy
    Howard L Kaufman
    J Clin Oncol 24:2230-2. 2006
  51. ncbi Integrating bench with bedside: the role of vaccine therapy in the treatment of solid tumors
    Howard L Kaufman
    J Clin Oncol 23:659-61. 2005
  52. ncbi Management of metastatic malignant melanoma of the bladder
    Christopher S D Lee
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA
    Urology 62:351. 2003
    ..Symptomatic bladder melanoma should be aggressively treated to allow for systemic immunotherapy, which can provide durable responses...
  53. pmc The contralateral sentinel node
    Ian K Komenaka
    Section of Breast Surgery, Indiana University Cancer Center, Indianapolis, Ind 46202, USA
    Can J Surg 48:416-7. 2005
  54. ncbi Combination interleukin-2 and interleukin-12 induces severe gastrointestinal toxicity and epithelial cell apoptosis in mice
    Howard L Kaufman
    Department of Surgery, Albert Einstein College of Medicine, Bronx, New York 10461
    Cytokine 17:43-52. 2002
    ..Understanding the pathologic changes associated with combination cytokine therapy may lead to strategies that prevent toxicity while maintaining therapeutic effects...
  55. ncbi Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy
    Selma Ugurel
    Department of Dermatology, Julius Maximilians University, Wurzburg, Germany
    Cancer Immunol Immunother 57:685-91. 2008
    ..This study was aimed at evaluating the potential impact of this gene polymorphism on disease progression and treatment outcome in patients with melanoma...
  56. ncbi Administration of vaccinia virus to mice may cause contact or bedding sentinel mice to test positive for orthopoxvirus antibodies: case report and follow-up investigation
    Diane J Gaertner
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461 1602, USA
    Comp Med 53:85-8. 2003
    ..The use of VV in animal facilities must be managed carefully since the available serologic tests do not distinguish between VV and EV, an exotic agent of major concern to laboratory animal facilities...
  57. ncbi Current approaches to novel therapeutics in pancreatic cancer
    Corina E Akerele
    Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York 10461, USA
    Invest New Drugs 21:113-29. 2003
    ..The article discusses the current knowledge of the biology of this lethal disease, its impact on treatment options, and explores novel therapeutic modalities that are likely to improve outcomes and survival for patients in the future...
  58. ncbi Management of metastatic melanoma to the breast with high-dose interleukin-2 and surgical resection
    Ian K Komenaka
    Breast J 11:158-9. 2005

Research Grants1

  1. ANTIGEN PRESENTATION BY CEA DIRECTED TUMOR VACCINES
    Howard Kaufman; Fiscal Year: 2002
    ..Nathenson as they pertain to peptide purification. Ultimately, this will strengthen his long-term goals of establishing a basic tumor immunology laboratory dedicated to tumor vaccine development. ..